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ABSTRACT   
 
BACKGROUND: Prostatic carcinoma carries a high morbidity 
and mortality if it is not diagnosed early.  In resource limited 
countries, patients are at increased risk of being diagnosed late as 
they are operated for presumed benign prostatic hyperplasia. The 
information on the magnitude and risk factors of this problem in 
our setting could assist in the overall optimization of care of 
patients at risk.   
METHODS: A retrospective study of patients who underwent 
prostatectomy for presumed benign prostatic enlargement was 
done at Bugando University Hspital in Tanzania. Patients’ age, 
creatinine levels, urological Ultrasound, prostate specific antigen 
and Biopsy results were analyzed using STATA 11. The prevalence 
of incidental prostatic cancer was calculated and logistic 
regression was done for factors associated with incidental prostatic 
cancer. 
RESULTS: In total, 152 patients were included in this study. The 
median age was 69 (SD 9.4) years, 16 (10.53%,) and 49 (32.24%) 
participants had Hydronephrosis and elevated creatinine levels 
respectively. Eighty six (58.56%) patients had PSA >10 ng/mL and 
in total; 33 (21.71%) had incidental prostatic carcinoma. The 
incidental prostatic carcinoma was independently associated with 
age of 70- 80years (AOR=2.8, p = 0.013) and PSA levels >10ng/mL 
(AOR=3.2, p=0.014). 
CONCLUSIONS: The prevalence of incidental prostatic 
carcinoma is high among patients undergoing transurethral 
prostatectomy for presumed benign prostatic hyperplasia in 
Tanzania with increased risk at age of 70-80 years and among 
those with PSA >10ng/mL. A national awareness campaign 
coupled with focused screening of patients above 60 years could 
increase the detection rate of prostatic carcinoma and reduce the 
magnitude of incidental diagnosis of this disease.   
KEYWORDS: Incidental prostatic carcinoma, PSA, Tertiary level 
hospital, Tanzania 
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Prostatic carcinoma is a common cause of 
morbidity and mortality among ageing population 
of male patients; with its prevalence and 
incidence varying globally depending on 
diagnostic advances (1). With advanced 
diagnostics in the developed world, prostatic 
carcinoma is reported to be one of the three most 
common carcinomas in men and one of the 
leading  causes of cancer related deaths (2). 
Although the rates of prostatic carcinoma in 
developing countries are on increment, most cases 
are likely to be missed in resource limited 
countries due to  the current diagnostic limitation 
(3) making the magnitude of the problem non-
representative and much lower as compared to 
developed countries. 
In an autopsy study conducted by Alexandre 
and associates among men who died of causes 
other than prostate carcinoma, more than 35% of 
the samples had prostate cancer and most patients 
(25-51%)  had advanced lesions of  Gleason score 
7 or above. In this study, more than 60% of those 
who were older than 80 years had prostatic cancer 
(4). Stamatiou et al., having assessed the 
prevalence of prostatic carcinoma in autopsy 
tissues, reported an age independent prevalence of 
18.8%; with highest rate of 56.8% in the oldest 
age group (5). Another study by Haas and 
colleagues, involving 164 autopsy prostates, 
indicated that 47 (29.0%) samples had prostate 
carcinoma and 20 (12.2%) of them were clinically 
significant by histological criteria (6). These 
studies suggest that most patients with prostatic 
carcinoma go unnoticed and thus making a timely 
diagnosis of this malignancy an ongoing 
important clinical challenge, which is even more 
so in resource limited settings. 
The available prevalence rates of prostatic 
carcinoma in live subjects from earlier studies are 
reported from examination of surgically obtained 
tissues, at times among patients who had not been 
suspected at all of  having the malignancy before 
surgery. For example, earlier in 1992 Bostwick 
and colleagues, having assessed association 
between benign prostatic enlargement (BPH) and 
prostatic carcinoma, found that  up to 25% of the 
patients who underwent  Trans Urethral Resection 
Prostatectomy (TURP) for presumed BPH had 
prostatic carcinoma (7).  Furthermore, among 
patients who underwent surgery for presumed 
bladder cancer, 25-40% of them were found to 
have associated prostatic carcinoma (8,9). 
While clinical presentations are highly non- 
specific for earlier stages of prostatic carcinoma, 
digital rectal examination (DRE) (10) and the 
available sonographic modalities are less sensitive 
to pick these manageable lesions. DRE with 
prostate specific antigen (PSA) coupled could 
increase the rate of detection and subsequently 
subject patients to biopsy  for confirmation (11). 
DRE findings of either presence of a nodule, 
prostatic asymmetry, change in prostatic texture, 
bogginess of the prostate or seminal vesicles  and 
adjacent organs have been shown to be highly 
suggestive of malignant growth (12). Biopsy and 
histologic examination in this subset  of patients 
would therefore confirm the diagnosis and 
determine the Gleason score based on the extent 
to which the epithelium assumes a normal 
glandular structure (13). Even with this body of 
information, the literature on the magnitude of 
this problem is still scarce in our setting. This 
study therefore was designed to determine the 
prevalence and associated factors of incidentally 
diagnosed prostatic carcinoma among patients 
who underwent TURP at a tertiary level hospital 
in Northwestern Tanzania.  
 
MATERIALS AND METHODS 
 
Study design and setting: This was a 
retrospective hospital based cohort study which 
was conducted at Bugando Medical Center 
(BMC) in Mwanza Tanzania. BMC is a consultant 
and teaching hospital for the Lake and Western 
zones of the United Republic of Tanzania. It is 
situated along the shores of Lake Victoria in 
Mwanza City. The hospital has a capacity of 1000 
beds with approximately 1000 employees. It is a 
referral center for tertiary specialists care for six 
regions, including Mwanza, Mara, Kagera, 
Shinyanga, Tabora, Kigoma and Simiyu. It serves 
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a catchment population of approximately 16 
million people. Urology is a super specialized 
department which works in collaboration with 
internal medicine specialties at Bugando 
university hospital. Patients attended are usually 
referred in from the second level hospitals. 
Routinely patients with obstructive prostatic 
enlargement undergo urological ultrasound 
(UTS), renal function testing, screening for 
infection with Full Blood count and urinalysis. 
PSA is only done for selected cases which are 
suspicious of malignant prostatic enlargement. 
Most patients with presumed BPH undergo TURP 
as a preferred modality to open prostatectomy as 
it has shorter hospital stay. Prostate tissues are 
subsequently submitted for histological 
evaluation, and patients found to have prostatic 
carcinoma undergo surgical hormonal 
manipulation. Some patients are also put on 
medical hormonal manipulation when affordable, 
and radical prostatectomy is not readily done. 
 
Study population: All patients who underwent 
TURP in 2015 for presumed BPH were included 
in this study. Tissues obtained from patients 
undergoing prostatectomy are usually submitted 
for histological examination on routine bases. 
Patients who underwent TURP for known 
prostatic carcinoma and those whose histological 
details were missing were excluded. 
 
Sample size, enrolment and data collection: A 
minimum sample size of 100 patients was 
estimated from Kish Lisle formula (1965) for 
cross sectional studies, assuming an incidental 
carcinoma prevalence of 15% according to 
previous studies (7,14), with a tolerable error of 
0.05 at 95% confidence interval (CI). A urological 
registry was used to identify all patients who 
underwent TURP during the study period and 
their identifiers were used to trace their files and 
histological results. From the files, data of 
research interest including age, renal function test, 
PSA results, Urological UTS results, amount of 
prostatic tissue ressected and histological results 
were retrieved and recorded in a special tool. The 
details on histology results including the 
percentage of biopsy with malignancy cells, 
Gleason score depending on the extent to which 
the epithelium assumed a normal glandular 
structure and Gleason sum were noted. 
 
Data management: The data were double entered 
and cleaned using Epi data version 3.1, and 
STATA version 11 (Stata Corp LP, college 
station, TX) was used for analysis. In this study, 
histological result with prostatic carcinoma in  
<5% of the biopsy was recorded as T1a while 
those with >5% were recorded as T1b (15). The 
Gleason score of 2-4 was coded as low grade 
(well differentiated),  while score of 5-7  and  8-
10 were coded as moderate (moderately 
differentiated) and high grade (poorly 
differentiated) respectively as used in other study 
(13). The PSA results were categorized into two 
with 7ng/mL as a cutoff point as used previously 
(16). Continuous variables were summarized as 
means with standard deviations (SD) and 
categorical variables were expressed as 
proportions with percentages. The proportion of 
patients with incidentally diagnosed prostatic 
carcinoma was calculated and univariate followed 
by multivariate logistic regression model was 
performed to determine the odds ratios and 95% 
CI for factors associated with incidental prostatic 
carcinoma. All factors with p<0.2 in the 
univariate analysis were included in the 
multivariate model. Factors were said to have a 
significant statistical association if the p value 
was less than 0.05 in the final model. 
 
Ethical consideration: The permission to 
conduct this study and publish its results was 
obtained from the joint research and Ethical 
Board of the Catholic University of Health and 
Allied Sciences (CUHAS) and Bugando Medical 
Center (BMC).  The patients’ files were handled 
by researchers alone and patients’ identifiers were 





Demographic and clinical characteristics of 
152 study participants : In the year 2015, a total 
of 152 patients underwent TURP for presumed 
BPH and all were included in this study. The 
mean age of study participants was 69 (SD 9.4) 
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years and about two thirds; 101 (66.44%) of them 
were between the age of 60 to 80 years. All 
patients were operated following obstructive 
prostatic symptoms, where 16 (10.53%) were 
found to have Hydronephrosis, and 49 (32.24%) 
had elevated creatinine levels. Of the study 
participants, 86 (56.58%) had elevated PSA levels 
>10 ng/mL with a mean level of 18.5 (SD 
22.8)ng/mL as summarized in Table 1.  
 
Table 1: General demographic and clinical 
characteristics of 152 study participants.  
 
Variable   Frequency Mean(SD) or 
percent 
Age in years 152 69 (9.4) 
Age group   
 <60 years 30 19.74 
 60-70 years 55 36.18 
 70-80 years 46 30.26 
 >80 years 21 13.82 
Hydronephrosis   
 YES 16 10.53 
 NO 136 89.47 
Creatinine levels   
Mean (mmol/dL) 152 91.1 (42.9) 
 >120mmol/dL 49 32.24 
 <120mmol/dL 103 67.76 
PSA level    
Mean (ng/mL) 152 18.5 (22.8) 
 >10ng/mL 86 56.58 
 <10ng/mL 66 43.42 
Mean prostate size 
(G) 
152 92.7 (59.7) 
Histology results   
 CA prostate 33 21.71 
 BPH 119 78.29 
Tumor percent   
 >5% of tissue 
(T1b) 
11 33.33 
 <5% of  
tissue(T1a) 
22 66.67 
Gleason score   
 Grade 1 (2-4) 4 12.12 
 Grade 2 (5-7) 11 33.33 
 Grade 3 (8-10) 18 54.55 
¶BPH: Benign prostatic hyperplasia; CA: Carcinoma; 
CI: Confidence interval; CR: Creatinine; G: Grams; 
IQR: Interquartile range; OR: Odds ratio; PSA: Prostatic 
specific antigen 
Prevalence and associated factors of incidental 
prostatic carcinoma: In this study, a total of 33 
(21.71%) patients operated for presumed BPH 
were found to have incidental prostatic carcinoma 
(Table 1). The T1a tumors were more common at 
ages <65 years (98.1% vs. 89.8%) whereas T1b 
was more common at ages >65years (10.1% vs. 
1.9%) with a Pearson ratio (Pr) of 0.05 (Figure 1). 
Increased tendency of having poorly 
differentiated incidental carcinoma was also 
observed among patients older than 65 years 
(13.3% vs. 9.3%, pr =0.5) as summarized in 
Figure 2. The odds of having incidentally 
diagnosed prostatic carcinoma were 
independently associated with age between 70 and 
80 years (AOR=2.8, p = 0.013) and PSA levels of 
more than 10ng/mL (AOR=3.2, p=0.014). The 
difference in distribution of other factors was not 
statistically significant as summarized in Table 2.  
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Table 2: Factors associated with incidentally diagnosed prostatic carcinoma among 152 participants who 
underwent TURP for presumed BPH. 
 
Variable Incidental  Prostate Carcinoma Un adjusted Adjusted 
YES (n=33) NO (n=119) OR (95%CI) P- Val OR(94%CI) P-Val 
Mean Age (Y) 71 (8.0) 68 (9.6) 1.0(0.9-1.1) 0.071 0.9 (0.9-1.0) 0.92 
Age Group (Y)       
 <60 years 02 (06.06) 28 (23.53) 0.2 (0.0-1.0) 0.040   
 60-70 years 11 (33.33) 44 (36.97) 0.9 (0.4-1.9) 0.700   
 70-80 years 17 (51.52) 29 (24.37) 3.3 (1.5-7.3) 0.003 2.8 (2.5-6.4) 0.013 
 >80 years 03 (09.09) 18 (15.13) 0.6 (0.2-2.0) 0.379   
Hydronephrosis       
 YES 04 (12.12) 012 (10.08)     
 NO 29 (87.88) 107 (89.92) 1.2 (0.4-4.0) 0.736   
CR levels       
Mean (mmol/dL)  103 (79.4) 87.8(25.2) 1.0 (0.9-1.0) 0.127 1.0 (0.9-1.1) 0.313 
 >120 mmol/dL 13 (39.39) 36 (30.25)     
 <120 mmol/dL 20 (60.61) 83 (69.75) 1.5 (0.7-3.3) 0.322   
PSA Levels        
Mean (ng/mL)  34.1(26.7) 13.4 (18.8) 1.1 (1.0-1.2) <0.001 1.0 (1.0-1.1) 0.33 
 >10ng/mL 26 (78.79) 60 (50.42)     
 <10ng/mL 07 (21.21) 59 (49.58) 3.7 (1.5-9.0) 0.005 3.2 (1.3-8.1) 0.014 
Prostate size (G) 83.4 (51.1) 95.2 (61.9) 1.0 (0.9-1.0) 0.369   
Biopsy Size (G) 15.4(18.8) 20.2(26.2) 1.0 (0.9-1.1) 0.352   
 
¶BPH: Benign Prostatic Hyperplasia; CI: Confidence interval; CR: Creatinine; G: grams; OR: Odds ratio; PSA: Prostatic 





Figure 2:  Distribution of Gleason grades by age cutoff of 65 years 
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The objective of this study was to determine the 
prevalence and assess the associated factors of 
incidental prostatic carcinoma among patients 
operated for presumed BPH. Several studies have 
had comparable findings. The prevalence from 
this study  is relatively similar with a 
prevalence rate of 25% reported earlier in 
1992 by Bostwick and colleagues among 
patients who underwent TURP (7). However, 
compared to our finding, a much lower  
prevalence of 1.4% of incidental prostatic 
carcinoma was reported recently by Otto and 
colleagues from the United States of America 
(14). Other lower prevalence rates include 
those reported from Brazil in 2006 where 
6.2% of patients who underwent TURP had 
incidental prostatic carcinoma (17), and UK 
in 2009  where 11.4% prevalence rate of 
incidentally diagnosed prostatic carcinoma 
was reported among  patients operated for 
presumed BPH (16). Compared to our 
finding, a higher prevalence of 40% was 
reported previously in 1996 among patients 
operated for bladder cancer (8). The 
differences in prevalence of incidental 
prostatic carcinoma in these studies can 
largely be attributed to the differences in 
diagnostics advances, noting here that most 
findings from studies that were prior use of 
PSA report much higher prevalence of 
incidentally diagnosed prostatic carcinoma. In 
support of this observation, Jones and 
colleagues in their study also found that more 
prostatic carcinomas were incidentally 
diagnosed before the advent of PSA (14.9% 
vs. 5.2%) (18).  
A number of factors were assessed for 
potential association with incidentally diagnosed 
prostatic carcinoma. It was found in the current 
study that advanced age and elevated PSA levels 
had a significant association with incidentally 
diagnosed prostatic carcinoma. These findings are 
consistent with those reported by Bright and 
colleague in 2009 form UK where advanced age 
(mean age 76 vs. 71) and raised PSA levels were 
also found to be predictive of Incidentally 
diagnosed prostatic carcinoma (16). It was also 
reported in Brazil that advanced mean age (73.9 
vs. 68.0, p=0.003) and suspicious rectal 
examination (23.0% vs. 3.4%, p=0.016) were 
significantly associated with incidental finding of 
Prostatic carcinoma. However, in this study, the 
PSA levels did not have any significant 
association with incidental prostatic carcinoma as 
found in other studies, and the authors thought 
that this could be explained by a longer time of 
indwelling bladder catheter before surgery which 
could also cause high levels PSA (17).  
These results are clinically important 
especially in resource limited setting like ours 
suggesting that as many as 21.6% of the 
malignant prostatic tumors are potentially missed 
among patients presenting with obstructive 
prostate presumed to be BPH. This rate is 
significantly higher as compared to those from 
resource rich countries (14,17), and strategies 
should be devised to increase the detection rate of 
this disease at its earliest and potentially 
manageable stage. In resource limited settings like 
Tanzania where PSA is not readily available, a 
targeted PSA screening could be useful in early 
identification of patients who can benefit from 
biopsy and early treatment.  Prior studies have 
indicated that PSA done in patients with 
suspicious per rectal examination at a risk age still 
significantly  increases the detection rate before 
surgery thus reducing  the rate of incidentally 
diagnosed prostatic carcinoma (17-19). While in 
the index study the age group of 70-80 years was 
the most associated factor with incidental 
prostatic carcinoma, previous studies had 
indicated that any age above 65 years is at highest 
risk of the most advanced local prostatic lesions 
with poor outcome. For instance, in 2016,  Perera 
and colleagues showed  that T1b’s were more 
common among ages above 65 years with highest 
Gleason score of more than 7 (15). Our study  had 
similar observation that patients who were older 
than 65 years were as well more likely to have 
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T1b tumors as compared to those younger than 
65years with an increased tendency to have 
poorly differentiated prostatic carcinoma than 
their younger counter parts. Ahmad and 
colleagues from Ireland in 2012 in addition found 
that the survival rate was significantly reduced 
among those patients with these advanced lesions 
(20). In this study, it was shown that with an 
overall survival of 88% at 10 years of watchful 
waiting, the survival rate was only 50% among 
those patients with T1b incidental prostatic 
carcinoma with increased cancer specific 
mortality of 20%.  
Most prostatic carcinoma diagnosed among  
younger patients have also been shown to be of 
less advanced malignant lesions of T1a (15). This 
is similar with our finding where we also 
observed that younger patients  had more of the 
T1a lesions compared to those older than 65 
years. Patients diagnosed with these earlier 
lesions have been shown to have a much better 
outcome on treatment, with radical prostatectomy 
being the preferred modality to TUPR (21,22). In 
2011, Bill-Axelson and colleagues could show 
that patients who underwent radical prostatectomy 
following early diagnosis of their prostatic cancer 
had a significant reduction of mortality (23). In 
2014, Bill-Axelson et al. additionally found that  
patients who were diagnosed and underwent 
prostatectomy at ages younger than 65 years had a 
reduced mortality rate by more than 25% after 23 
years of follow-up  (24). In our setting, we could 
also reduce the rate of incidentally diagnosed 
carcinoma of prostate by devising strategies that 
address a focused PSA screening of patients older 
than 60 years with suspicious DRE and subject 
them to biopsy for confirmatory histology 
examination. This study had a number of 
limitations. Being a single center study, the results 
from this study may not be generalizable. Also, 
being a retrospective study, missing data was a 
common problem. Additionally, the outcome of 
these patients could not be determined. However, 
this is one of the fewer studies that have assessed 
the prevalence of incidentally diagnosed prostatic 
carcinoma in Tanzania. 
  In conclusion, this study has shown that 
incidental prostatic carcinoma is very prevalent 
among patients operated for presumed benign 
prostate enlargement. The risk of incidentally 
diagnosed prostatic carcinoma is highest at an age 
group of 70-80 years and those with elevated PSA 
levels above 10ng/mL. Strategies to reduce this 
magnitude are required. A national awareness 
campaign coupled with focused PSA screening of 
patients above 60 years could potentially increase 
the detection rate of prostatic carcinoma and 
therefore reduce the magnitude of the incidental 
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